~~<i id='E50BADA42B'><strike id='E50BADA42B'><tt id='E50BADA42B'><pre id='E50BADA42B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：fashion 2025-10-06 08:04:06 - browse：2383

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Listen: A conversation with researcher Kevin Esvelt on biosecurity

hotspot

entertainment

leisure time

focus

KatiePalmer,STAT(left)moderatingtheDoctorvs.ChatGPTsessionduringthe2023STATSummit.STATGenerativeAIto

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

H5N1 virus can be tracked in retail milk, scientists say

ASCO eve: Let’s set the table for this year's meeting

Investigation reveals sickle cell patients pressured into sterilizations

Questions and answers about ramping up H5N1 bird flu vaccine

STAT Summit: The economic case for universal basic health care

hotspot

focus

hotspot

Hollywood unions extend contract negotiations for actors

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Activists slam private health insurers over coverage restrictions

UnitedHealth argues against case alleging wrongful AI care denials

Medical records are filled with copy

Merck, Daiichi strike cancer drug pact worth up to $22 billion

23andMe had bad news about my health. I wish a person had delivered it

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Virginia high school admissions case could be legal follow

Citing H5N1 threat, CDC urges peak flu monitoring this summer

hotspot

UnitedHealth argues against case alleging wrongful AI care denials

STAT Summit: Ending the crisis of Black deaths in the U.S.

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Making the case for fair compensation in clinical trials

ASCO eve: Let’s set the table for this year's meeting

entertainment

leisure time

focus

focus